[{"address1": "20 Park Plaza", "address2": "Suite 424", "city": "Boston", "state": "MA", "zip": "02116", "country": "United States", "phone": "617 744 4400", "website": "https://www.cervomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. John J. Alam M.D.", "age": 61, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 680255, "exercisedValue": 0, "unexercisedValue": 9071}, {"maxAge": 1, "name": "Dr. Sylvie L. Gregoire Pharm.D.", "age": 62, "title": "Co-Founder & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 352432, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William Robert Elder J.D.", "age": 40, "title": "CFO & General Counsel", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 407553, "exercisedValue": 0, "unexercisedValue": 4087}, {"maxAge": 1, "name": "Dr. Robert J. Cobuzzi Jr., Ph.D.", "age": 58, "title": "COO & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 386600, "exercisedValue": 0, "unexercisedValue": 4087}, {"maxAge": 1, "name": "Ms. Kelly  Blackburn M.H.A.", "age": 59, "title": "Senior Vice President of Clinical Development", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 404940, "exercisedValue": 0, "unexercisedValue": 4087}, {"maxAge": 1, "name": "Dr. Mark A. De Rosch Ph.D.", "age": 60, "title": "SVP of Regulatory & Government Affairs & Program Management", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claudia  Ordonez M.D.", "age": 57, "title": "Senior Vice President of Medical Science", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 6, "shareHolderRightsRisk": 6, "overallRisk": 7, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.93, "open": 1.89, "dayLow": 1.81, "dayHigh": 1.95, "regularMarketPreviousClose": 1.93, "regularMarketOpen": 1.89, "regularMarketDayLow": 1.81, "regularMarketDayHigh": 1.95, "forwardPE": -0.9866491, "volume": 601324, "regularMarketVolume": 601324, "averageVolume": 317514, "averageVolume10days": 1499290, "averageDailyVolume10Day": 1499290, "bid": 1.85, "ask": 1.92, "bidSize": 300, "askSize": 100, "marketCap": 15682106, "fiftyTwoWeekLow": 1.81, "fiftyTwoWeekHigh": 26.38, "priceToSalesTrailing12Months": 1.5578432, "fiftyDayAverage": 11.1396, "twoHundredDayAverage": 16.7124, "currency": "USD", "enterpriseValue": -30974796, "profitMargins": -1.18682, "floatShares": 3891391, "sharesOutstanding": 8253740, "sharesShort": 1915148, "sharesShortPriorMonth": 1482235, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.23200001, "heldPercentInsiders": 0.35199, "heldPercentInstitutions": 0.42681, "shortRatio": 15.72, "shortPercentOfFloat": 0.35799998, "impliedSharesOutstanding": 8253740, "bookValue": 5.529, "priceToBook": 0.34364262, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -11947179, "trailingEps": -2.17, "forwardEps": -2.54, "lastSplitFactor": "2:3", "lastSplitDate": 1692230400, "enterpriseToRevenue": -3.077, "52WeekChange": -0.75672215, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRVO", "underlyingSymbol": "CRVO", "shortName": "CervoMed Inc.", "longName": "CervoMed Inc.", "firstTradeDateEpochUtc": 1211549400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c18b10b1-f207-3967-85cb-838eaa2581f8", "messageBoardId": "finmb_280597237", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.9, "targetHighPrice": 42.0, "targetLowPrice": 4.0, "targetMeanPrice": 24.4, "targetMedianPrice": 30.0, "recommendationMean": 2.75, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 46656904, "totalCashPerShare": 5.653, "quickRatio": 14.453, "currentRatio": 15.035, "totalRevenue": 10066550, "revenuePerShare": 1.349, "returnOnAssets": -0.2599, "returnOnEquity": -0.43278, "freeCashflow": -6635316, "operatingCashflow": -11018363, "revenueGrowth": 0.271, "grossMargins": -0.44708002, "operatingMargins": -2.78194, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]